Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-16-2026-01_58_09-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Lilly bets up to $800M for BioArctic’s brain delivery tech
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

BioSpace

Eli Lilly plans to use BioArctic's technology to shuttle an undisclosed drug candidate into the brain.

Neuroscience

Read full story

pharminent June 22, 2026 (Last updated: June 22, 2026)

BioSpace

Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain.

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Boehringer advances duo for aggressive cancers into phase 3
Next: AbbVie climbs post-Allergan M&A peak with Apogee buy

Related Stories

  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

pharminent June 22, 2026
  • M&A / Deals

Sun Pharma to acquire Innovcare Lifesciences for $28.7m

pharminent June 22, 2026

You May Have Missed

  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
  • Clinical Data

Boehringer advances duo for aggressive cancers into phase 3

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.